ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
First bronchiectasis patient dosed in Phase III trial to study brensocatib
December 04, 2020The first patient with bronchiectasis has been dosed in the Phase III ASPEN study of brensocatib, a reversible inhibitor of dipeptidyl peptidase 1. -
EC Grants Authorization for ARIKAYCE Liposomal Nebulizer Dispersion for NTM Lung Infections
November 06, 2020Insmed Incorporated announced the European Commission (EC) has granted marketing authorization for ARIKAYCE® Liposomal 590 mg Nebulizer Dispersion for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium ...
Pharma Sources Insight January 2025
